MorphoSys 9-Month Profit Rises

MorphoSys AG (MOR) Wednesday reported nine-months net profit of 114.4 million euros or 3.53 euro per share, compared to last year's loss of $52.7 million euros or 1.67 euro per share.

EBIT for the period was 101.8 million euros, compared to an EBIT loss of 52.7 million euros last year.

Group revenues for the first nine months of 2020 totaled 291.7 million euros, up from 60.7 million euros last year.

Third-quarter net loss was 65.3 million euros or 2.00 per share, wider than last year's loss of 24.2 million euros or 0.76 euros per share.

Group revenues for the third quarter increased to 22.0 million euros from 12.5 million euros last year, driven largely by the first-time recognition of Monjuvi product sales and from service fees for the assignment of personnel to R&D collaboration.

Earnings before interest and taxes for the Group amounted to a loss of 61.7 million euros, wider than last year's EBIT loss of 27.0 million euros.

Looking forward to 2020, MophoSys now expects revenues of 317 million to 327 million euros, and an EBIT 10 million to 20 million euros, Previously, the company expected revenues of 280 million to 290 million euros and EBIT loss of 15 million to earnings 5 million euros.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mallinckrodt plc announced Wednesday that the U.S. Food and Drug Administration or FDA has approved StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for the treatment of adult patients with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated. Worldwide 5G mobile subscriptions are estimated to exceed 580 million by the end of 2021, according to the Ericsson Mobility Report. With subscriptions increasing at a rate of about a million per day, 5G remains on track to become the fastest adopted mobile generation in history. The growth in subscriptions is being lead by China, North America and the Gulf Cooperation Council markets. Elanco Animal Health Inc. (ELAN) and veterinary biopharmaceutical company Kindred Biosciences, Inc. (KIN) announced Wednesday they have entered into a definitive agreement for Elanco to acquire Kindred for $9.25 per share, or approximately $440 million. The acquisition further accelerates Elanco's...
Follow RTT